IPM Take
Breast cancer is moving toward a more honest model of endocrine resistance: identify the biology that is escaping treatment and change strategy accordingly. ESR1 cannot stay buried inside a genomic report. If it increasingly predicts where oral SERDs deliver the greatest benefit, testing access and timing become treatment policy.
Executive Summary
The Phase III evERA trial, published in The New England Journal of Medicine, randomized 373 patients with ER-positive, HER2-negative advanced breast cancer following prior CDK4/6 inhibitor plus endocrine therapy. Median progression-free survival in the ESR1-mutated population was 10.0 months with giredestrant plus everolimus versus 5.5 months with standard endocrine therapy plus everolimus, producing a hazard ratio of 0.38. In the overall population, median PFS was 8.8 versus 5.5 months, with a hazard ratio of 0.56. Overall-survival data remain immature.
Why it matters
- Patients / advocates: A fully oral regimen could delay progression after endocrine resistance develops.
- Clinicians: ESR1-mutated disease appears particularly sensitive to the giredestrant strategy.
- Diagnostics / pathology: Molecular information must arrive at the point where endocrine resistance is being managed.
- Payers: Biomarker-directed use may become central to defining clinical and economic value.
Endocrine resistance used to be described as if the tumour simply “stopped responding.”
That language is becoming inadequate.
Breast cancer increasingly tells us how it is escaping. ESR1 mutation is one of the clearest examples, and evERA shows why that matters clinically.
Among patients whose tumours carried ESR1 mutations, median progression-free survival nearly doubled with giredestrant plus everolimus: 10.0 months versus 5.5 months. The benefit remained significant in the overall study population, but the ESR1 group is where the biology becomes impossible to ignore.
This is the more mature version of precision oncology.
Not “sequence everything and hope something interesting appears.”
Test a resistance mechanism that changes a treatment decision.
That distinction is important because molecular testing can easily become expensive decoration. A biomarker earns its place when the system can connect result to action.
Giredestrant is still investigational in this setting, with FDA decisions pending later this year. Overall survival remains immature. Everolimus toxicity does not disappear because the endocrine partner is newer.
But the direction is increasingly clear.
Breast-cancer care after CDK4/6 inhibitors is becoming less about asking which endocrine drug comes next and more about asking what resistance biology is now driving the disease.
The test is becoming part of the treatment.
